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In registration trials of pegylated interferons a2a and a2b plus
ribavirin, 10–14% of patients had to discontinue therapy due to
a number of adverse events (AEs). Thrombocytopenia is a fre-
quent laboratory AE in treated patients. Although baseline and
treatment-induced low platelet counts are a rather common phe-
nomenon in patients with advanced liver disease and compen-
sated cirrhosis, treatment associated, serious bleeding episodes
are rare but information on the accurate risk is limited. Yet, in
anticipation of thrombocytopenia associated bleeding, product
labels of pegylated interferons recommend a dose reduction
when platelet counts reach <50,000/ll (as reported in 3–6% of
patients) and treatment discontinuation altogether at a platelet
count of 625,000/ll. It is well recognized that dose reduction
of anti-viral therapy signiﬁcantly compromises the success rate
of sustained viral response (SVR). As a result and in an era of indi-
vidualized treatment, more clinicians are trying to stretch the
limits of the safety margins of interferon treatment in order to
improve SVR, especially in patients with compensated cirrhosis
and baseline thrombocytopenia, who have frequently been
excluded from clinical trials.
In this issue of the Journal, Roomer and co-workers have ret-
rospectively analyzed the correlation between baseline and iatro-
genic thrombocytopenia and the risk of major bleeding during
anti-viral therapy with pegylated interferons and ribavirin. Treat-
ment was associated with a mean platelet drop of 42% as com-
pared to 30–50% in the literature. The rate of grades 3 and 4
thrombocytopenia with platelet counts <50,000 and <25,000/ll,
respectively, reached 9.3% and 2.8%. This ﬁgure is marginally
higher compared to previous reports which ranged between 3%
and 6%. Yet, none of the thrombocytopenic patients in this study
developed serious bleeding. However, in a multivariate analysis,
platelet counts <50,000/ll and cirrhosis were associated with a
higher degree of minor bleeding including epistaxis, gingival
bleeding, hematoma, gastrointestinal bleeding (apparently con-
trolled), and vaginal bleeding. Finally, no serious bleeding was
observed in a subset of patients who started anti-viral therapy
with a baseline platelet count <80,000/ll. The authors conclude
that the safety margin of treatment in chronic HCV patients with
pegylated interferon and ribavirin and a platelet count <50,000/ll
should be reconsidered. Based on the presented data, no deﬁnite
conclusion can be drawn regarding the safety of anti-viral treat-Journal of Hepatology 20
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number of the nine patients studied was relatively small.
The results of this study are reassuring for patients with a
platelet count as low as 50,000/ll and important for clinicians
who treat HCV patients, especially those with splenomegaly,
advanced liver disease and compensated cirrhosis. Of special
importance is the observation that platelet counts remained rel-
atively stable between 25 and 50,000/ll in the 18 patients in
whom no interferon dose reduction was performed. This infor-
mation may also be relevant in view of the currently ongoing
phase III study with the thrombopoietin receptor agonist
Elthrombopeg. In 12/30 patients who developed a platelet count
<50,000/ll, a dose reduction was performed and apparently these
patients were more likely to develop a bleeding episode, although
of minor clinical signiﬁcance. The study has a number of
limitations. The authors have made some suggestions regarding
modiﬁcation of interferon dosing in the presence of thrombocy-
topenia. However, new guidelines regarding interferon dose
reduction and stopping rules must wait for a prospective study
and caution must be applied in the over-interpretation of the
results, especially in patients with grade 4 thrombocytopenia.
Furthermore, the information provided in this report was derived
from a heterogenous patient population with various HCV geno-
types who were treated by different regimens. No information
was presented regarding the success of anti-viral therapy in this
mixed cohort of thrombocytopenic and non-thrombocytopenic
patients. In conclusion, the incidence of severe thrombocytopenia
in this analysis of 321 patients with chronic HCV treated with
pegylated interferon and ribavirin was low and serious bleeding
was not observed.Coping with emerging resistance to add-on therapy with
lamivudine and adefovir in patients treated initially with
lamivudine and switched to adefovir monotherapy
In this issue of the Journal, Nae-Yun Heo and co-workers have
summarized their experience with anti-viral treatment of com-
pensated patients with chronic hepatitis B (CHB) who developed
sequential resistance, initially to lamivudine and than to adefovir
monotherapy. This population of 91 patients had a number of
lamivudine resistant mutations rtM204v/l and or rtl180M as well
as adefovir resistant mutations rtA181V/T and or rt236T (see
Table 1 for a detailed description). Forty-one of these patients
were treated with 100 mg lamivudine and 10 mg adefovir/day
(combination group) while 50 patients received Entecavir
0.5 mg/day (monotherapy group) for at least 12 months. Themost10 vol. 53 j 395–396
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important ﬁnding of this study is the high non-response rate to
anti-viral treatment observed already at 6 months of therapy in
51.2% of the combination group as compared to 16.0% in the
monotherapy group. Furthermore, at 12 months of treatment, an
inadequate virologic response was observed in 80.5% of the com-
bination group and even in 36.0% in the monotherapy group. ALT
normalization was similar in both groups at month 12, reaching
41.5% in the combination group and somewhat higher, but
statistically non-signiﬁcant in 58.0% of the monotherapy group.
Virologic breakthrough developed in 3/41 patients of the combi-
nation group and in 3/50 patients in the Entecavir group in whom
genotypic analysis revealed the presence of an rt184G or rtM260V
mutations together with lamivudine resistant rtM204V/l and or
rtl180Mmutations. Without going into further details of the anal-
ysis described in this report, the results should raise a red ﬂag
regarding the currently employed algorithms for treating lamivu-
dine and adefovir resistant CHB patients with a combination of396 Journal of Hepatology 201these drugs. Thus, in resistant patients originally treated with
lamivudine and then switched to adefovir, the add-on approach
of these two drugs is associated with development of multidrug
resistance which justiﬁes the exploration of new combinations
betweenmore potent anti-viral agents against HBV. Finally, in this
study, 6% of patients that switched to Entecavir developed resis-
tance within 12 months of therapy. This observation suggests that
despite its potent anti-viral properties in the treatment of naïve
patients, switching to lamivudine and adefovir in patients resis-
tant to Entecavir may indeed be associated with suboptimal
results.
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